All In Biotech

NDA 021762 · Organon LLC

Fosamax Plus D

Alendronate Sodium, Cholecalciferol · Oral · Vitamin D

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Apr 7, 2005

Approved uses

2

Original approval plus efficacy supplements

Registered trials

181

59 Phase 3, 7 recruiting

FAERS reports

2,769

2,562 serious, 128 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 3, 2026.

FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Limitations of use : FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. ( 1.3 ) Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.3 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX ® PLUS D is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, FOSAMAX PLUS D increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis FOSAMAX PLUS D is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.2) ] . 1.3 Important Limitations of Use FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. The optimal duration of use has not been determined. The safety and effectiveness of FOSAMAX PLUS D for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Mechanism: Alendronate Sodium Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • FOSAMAX PLUS D · ALENDRONATE SODIUM EQ 70MG BASE; CHOLECALCIFEROL 2,800 IU · TABLET, ORAL · Prescription
  • FOSAMAX PLUS D · ALENDRONATE SODIUM EQ 70MG BASE; CHOLECALCIFEROL 5,600 IU · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alendronate" as an intervention, any sponsor and status, largest first.

All 181 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • femur fracture1,410
  • fall811
  • osteoarthritis657
  • low turnover osteopathy622
  • hypertension552
  • arthralgia467
  • gastrooesophageal reflux disease438
  • intramedullary rod insertion429
  • osteoporosis428
  • depression406
  • anxiety404
  • pain in extremity397

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
200649
2007101
2008218
2009205
2010223
2011291
2012772
2013286
2014166
2015123
201672
201740
201850
201927
202024
202143
202228
202318
202413
20258
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fosamax Plus D (Alendronate Sodium/Vitamin D3)

2024 spending

$535K

Beneficiaries

580

1,838 claims

Per beneficiary

$923

$49.64 per unit

View as table
YearSpending
2020$0
2021$165,503
2022$662,987
2023$603,530
2024$535,473

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,034 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.